Gyre Therapeutics, Inc. (NASDAQ:GYRE) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weakening the ...

Unsurprisingly, Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a ...

GYRE is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of GYRE shares has decreased $0.03 since the market last closed. This is a 0.38 ...

Gyre Therapeutics is an under-the-radar biotech company that achieved its listing on the Nasdaq through a merger between Catalyst Biosciences and GNI Group. Gyre focuses on developing small-molecule ...